Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IDT Biologika

- PMLiVE

Enhertu to provide patients with vital targeted therapy option

Therapy receives FDA priority review as patients with HER2-mutant metastatic non-small cell lung cancer seek alternative treatment

- PMLiVE

GSK and CureVac sign deal with Germany for mRNA COVID-19 vaccines

The agreement is part of a Pandemic Preparedness Contract and means millions of vaccines can be produced at short notice during future public health emergencies

- PMLiVE

Gavi, MedAccess and the Open Society Foundations partner to support COVAX

COVAX has delivered more than 1.4 billion COVID-19 vaccines to 145 countries and territories

- PMLiVE

EMA and ECDC publish advice on fourth doses of mRNA COVID-19 vaccines

The regulators have concluded that there is not enough supporting evidence for an immediate fourth dose

- PMLiVE

FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

The second booster authorisation is for those aged 50 years and older to promote high levels of protection against COVID-19 in the most vulnerable groups

- PMLiVE

AstraZeneca to present new oncology data at AACR

The American Association for Cancer Research Annual Meeting takes place in New Orleans from 8-13 April 2022

- PMLiVE

CHMP recommends marketing authorisation for AZ’s Evusheld in the EU

The treatment can be used to prevent people contracting COVID-19 and can be given to adults and children aged 12 years and older

- PMLiVE

Pfizer agrees to supply UNICEF with up to 4 million courses of oral COVID-19 treatments

The deal is set to benefit to 95 low- and middle-income countries, pending authorisation or approval

- PMLiVE

FDA to review requirements for future booster shots for COVID-19

The meeting will be streamed live on the FDA’s YouTube channel and a webcast will be provided on the FDA website

- PMLiVE

Moderna applies to FDA for authorisation for second COVID-19 booster shot for all adults

The second booster shot would be for adults 18 years and over who have already had one authorised COVID-19 booster shot

- PMLiVE

AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris

The two companies will withdraw patent infringement proceedings filed with the US and Japan

- PMLiVE

MHRA grants approval for AstraZeneca’s Evusheld in the UK

It is the first antibody combination treatment authorised for use before exposure to COVID-19 infection in order to prevent disease licensed in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links